- Home
- IROH vs CUE Comparison
IROH vs CUE Comparison
Compare IROH & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IROH
- CUE
- Stock Information
- Founded
- IROH 2021
- CUE 2014
- Country
- IROH United States
- CUE United States
- Employees
- IROH N/A
- CUE N/A
- Industry
- IROH
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- IROH
- CUE Health Care
- Exchange
- IROH Nasdaq
- CUE Nasdaq
- Market Cap
- IROH 91.2M
- CUE 91.9M
- IPO Year
- IROH 2023
- CUE 2018
- Fundamental
- Price
- IROH $10.38
- CUE $1.28
- Analyst Decision
- IROH
- CUE Strong Buy
- Analyst Count
- IROH 0
- CUE 5
- Target Price
- IROH N/A
- CUE $5.00
- AVG Volume (30 Days)
- IROH 44.0K
- CUE 283.2K
- Earning Date
- IROH 01-01-0001
- CUE 03-10-2025
- Dividend Yield
- IROH N/A
- CUE N/A
- EPS Growth
- IROH N/A
- CUE N/A
- EPS
- IROH 0.20
- CUE N/A
- Revenue
- IROH N/A
- CUE $9,532,000.00
- Revenue This Year
- IROH N/A
- CUE $73.11
- Revenue Next Year
- IROH N/A
- CUE $11.02
- P/E Ratio
- IROH $53.07
- CUE N/A
- Revenue Growth
- IROH N/A
- CUE 149.53
- 52 Week Low
- IROH $9.97
- CUE $0.45
- 52 Week High
- IROH $11.11
- CUE $2.58
- Technical
- Relative Strength Index (RSI)
- IROH N/A
- CUE 46.30
- Support Level
- IROH N/A
- CUE $1.20
- Resistance Level
- IROH N/A
- CUE $1.50
- Average True Range (ATR)
- IROH 0.00
- CUE 0.12
- MACD
- IROH 0.00
- CUE -0.02
- Stochastic Oscillator
- IROH 0.00
- CUE 38.30
About IROH Iron Horse Acquisitions Corp. Common Stock
Iron Horse Acquisitions Corp is a blank check company.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.